Myeloma Center

Bibliography

Found 41 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is L  [Clear All Filters]
2007
Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN et al..  2007.  Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.. Br J Haematol. 138(5):640-3.
Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN et al..  2007.  Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.. Br J Haematol. 138(5):640-3.
Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F et al..  2007.  Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.. Leuk Lymphoma. 48(12):2330-7.
2008
Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S et al..  2008.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. Br J Haematol. 143(5):654-60.
Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S et al..  2008.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. Br J Haematol. 143(5):654-60.
Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S et al..  2008.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. Br J Haematol. 143(5):654-60.
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K et al..  2008.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood. 111(3):1101-9.
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K et al..  2008.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood. 111(3):1101-9.
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K et al..  2008.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood. 111(3):1101-9.
Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, Larow A, Pearse RN, Harpel J, Shore T, Schuster MW et al..  2008.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.. Biol Blood Marrow Transplant. 14(7):795-8.
Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, Larow A, Pearse RN, Harpel J, Shore T, Schuster MW et al..  2008.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.. Biol Blood Marrow Transplant. 14(7):795-8.
2009
Mark T, Martin P, Leonard JP, Niesvizky R.  2009.  Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.. Expert Opin Investig Drugs. 18(1):99-104.
2010
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
2012
A Wernicke G, Sabbas A, Kulidzhanov F, Shamis M, Golster Y, Niesvizky R, Lane J.  2012.  A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma.. HSS J. 8(2):169-74.
2013
Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R.  2013.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.. Leukemia. 27(8):1707-14.
Rosenbaum C, Jasielec J, Laubach J, Prada CPaba, Richardson P, Jakubowiak AJ.  2013.  Evolving strategies in the initial treatment of multiple myeloma.. Semin Oncol. 40(5):592-601.
Siegel D, Martin T, Nooka A, R Harvey D, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K et al..  2013.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.. Haematologica. 98(11):1753-61.
Richardson PG, Mark TM, Lacy MQ.  2013.  Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.. Crit Rev Oncol Hematol. 88 Suppl 1:S36-44.
2014
Palumbo A, S Rajkumar V, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC et al..  2014.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.. J Clin Oncol. 32(6):587-600.
Palumbo A, S Rajkumar V, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC et al..  2014.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.. J Clin Oncol. 32(6):587-600.
Palumbo A, S Rajkumar V, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC et al..  2014.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.. J Clin Oncol. 32(6):587-600.
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al..  2014.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al..  2014.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.